Nuvectis Pharma Inc Dossier
Qualitative Analysis
Business overview
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Fort Lee, New Jersey. The company is dedicated to the acquisition, licensing, and clinical development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis is currently advancing two primary drug candidates: NXP900, a highly selective, novel oral small molecule inhibitor of the SRC Family of Kinases (SFK) including SRC and YES1, which is currently in Phase 1b clinical development; and NXP800, a novel oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway, which is being evaluated in a Phase 1b study for patients with platinum-resistant, ARID1A-mutated ovarian cancer.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the NXP900 Phase 1b clinical program, which evaluates NXP900 as a monotherapy in molecularly and histologically-defined target tumors, and in combination with osimertinib (Tagrisso) for EGFR-mutated non-small cell lung cancer (NSCLC).
Expected impact: Establish clinical proof-of-concept for NXP900 as a highly selective c-Src and YES1 kinase inhibitor to overcome drug resistance in solid tumors.
Prioritizing the expansion of NXP800 (a novel GCN2 activator) Phase 1b cohorts to evaluate its therapeutic potential in platinum-resistant, ARID1a-mutated ovarian carcinoma and cholangiocarcinoma.
Expected impact: Address serious unmet medical needs in hard-to-treat oncology indications, leveraging its FDA Fast Track and Orphan Drug Designations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Nuvectis with exclusive worldwide commercial rights to develop and commercialize NXP900 and its associated derivatives.
Terms: Nuvectis paid an upfront fee of $3.5 million and is obligated to pay additional milestone-dependent payments and royalties on future sales, alongside up to £580,000 in research and development support.
Provides Nuvectis with exclusive worldwide commercial rights to develop and commercialize NXP800 and its derivatives.
Terms: Subject to milestone and royalty payments based on clinical, regulatory, and commercial achievements.